At a glance
Adults 18+ COVID-19 Vaccinations Administered
The projected pharmacy estimates are based on IQVIA†,‡ Longitudinal Prescription Claims (LRx) and vaccinations administered in retail pharmacies (including chain, mass merchandise, food stores, and independent pharmacies).§ The projected physicians' medical offices estimates are based on IQVIA's Medical Claims (Dx).±
Vaccinations administered in workplaces, community locations, long-term care settings, and other medical settings such as public health clinics are not represented in these data.
Weekly comparisons to previous season should take into account differences between seasons in vaccine availability dates. 2023–24 COVID-19 vaccines were first available mid-September 2023, and 2024–25 and 2025–26 COVID-19 vaccines were first available at the end of August 2024 and 2025, respectively.
- Figure 6. Weekly Cumulative Estimated Number of COVID-19 Vaccinations Administered in Retail Pharmacies and Physician Medical Offices Among Adults 18 Years and Older, by Season and Age-Group, United States. Data Source(s): IQVIA LRx and Dx.
*National estimates for retail pharmacies and physicians’ medical offices include vaccinations administered in 50 states and DC. National estimates for medical office vaccinations do not include doses where geographic information (i.e. which state the dose was administered in) was missing. Pharmacy data are through Friday of each week and medical office data are through Saturday of each week. Week ending dates for prior seasons are aligned to most closely match the current season’s week ending dates. For data privacy, IQVIA calculates age based on year of birth and everyone born in a given year is assigned January 1 as their date of birth.
†King, L. M., Bartoces, M., Fleming-Dutra, K. E., et al. (2020). Changes in US outpatient antibiotic prescriptions from 2011–2016. Clinical Infectious Diseases, 70(3), 370-377.
‡McLaughlin, J. M., Swerdlow, D. L., Khan, F., et al. (2019). Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States. Human vaccines & immunotherapeutics, 15(4), 841-849.
§Using the raw number of doses administered at a subset of retail pharmacies, IQVIA uses a proprietary projection methodology to estimate the projected number of vaccinations administered at all retail pharmacies. For the 2024–25 season, projected estimates were based on a subset of 37,556 pharmacies. The total number of retail pharmacies in the U.S. was estimated at 57,000 in 2022 (The retail pharmacy of the future | McKinsey. Accessed on 08.21.2025). The estimates include COVID-19 vaccinations that were billed to insurers (i.e. claims) or paid by cash. Projected pharmacy estimates are updated each week for the prior 13 weeks but an initial evaluation has shown that the number of doses changed minimally over time. Doses administered since August 27, 2025, are assumed to be the 2025–26 COVID-19 vaccine.
±Using the raw number of doses administered at the offices of a subset of physicians from American Medical Association (AMA) proprietary list, IQVIA uses a proprietary projection methodology to estimate the projected number of vaccinations administered in medical offices of all physicians from AMA's list. For the 2024–25 season, projected estimates were based on a subset of 21,332 AMA office-based physicians who administered COVID-19 vaccine. For context, for 2022–23, the number of office-based physicians in the U.S. is 691,382 (https://data.hrsa.gov/topics/health-workforce/nchwa/ahrf). The estimates include COVID-19 vaccinations that are claims-based only, and estimates are expected to increase over time for a given time period as claims are processed and adjudicated. Projected estimates are updated monthly and do not mature until about two months. This results in an increase or decrease in the initial or subsequent estimates for a given week. Evaluation of changes in IQVIA flu vaccination estimates over time during the 2022–23 season is available and indicates that the reported number of doses administered for a particular week increased 10.7% over the next few weeks.
^The recommendations for the 2025–26 COVID-19 vaccines include individual-based decision making with consideration for presence of underlying conditions and the higher risk for severe COVID-19 for individuals 6 months to 64 years. We are not able to assess the presence of factors that increase the risk for severe COVID-19 in these IQVIA data.